{
    "title": "Novartis heart failure treatment serelaxin fails in pivotal study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4337720/Novartis-heart-failure-treatment-serelaxin-fails-pivotal-study.html",
    "date": "2017-03-22",
    "keywords": [
        "heart",
        "serelaxin",
        "failure",
        "drug",
        "novartis",
        "trial",
        "approval",
        "blood",
        "condition",
        "reporting",
        "march",
        "treatment",
        "franchise",
        "flagship",
        "entresto",
        "business",
        "blow",
        "wednesday",
        "latestage",
        "blockbuster",
        "string",
        "union",
        "health",
        "food",
        "administration",
        "way",
        "gap",
        "diovan",
        "patent",
        "submission",
        "fda",
        "ice",
        "relaxahf2",
        "phase",
        "target",
        "failurethis",
        "disappointment",
        "upside",
        "zurich",
        "trader",
        "drugmaker",
        "percent",
        "stock",
        "emergency",
        "breath",
        "fluid",
        "bodythe",
        "cause",
        "hospitalisation",
        "age",
        "year",
        "hormone",
        "burden",
        "heartwe",
        "study",
        "efficacy",
        "need",
        "narasimhan",
        "head",
        "development",
        "officer",
        "novartiswe",
        "data",
        "understand",
        "learn",
        "program",
        "john",
        "revill",
        "pretterklieber",
        "editing",
        "brenna"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}